Osimertinib (Tagrisso) Osimertinib is a targeted cancer drug. It is pronounced oh-see-mer-tin-ib. It is also called Tagrisso. Osimertinib is a treatment for non small cell lung cancer (NSCLC). You may ...

Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib ...

Prior studies demonstrated osimertinib mesylate (Tagrisso, AstraZeneca) can extend survival compared with first- or second-generation EGFR TKIs.

Osimertinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of stage 1b to 3a non‑small‑cell lung cancer (NSCLC) after complete tumour resection. It is for ...

At 24 months, 57% (95% CI, 50 to 63) of the patients in the osimertinib–chemotherapy group and 41% (95% CI, 35 to 47) of those in the osimertinib group were alive and progression-free.

Tagrisso is one of the blockbuster drugs of AstraZeneca. NIPER, in its complete specification submitted with the Patent Office, said that one of the major concerns with the use of osimertinib mesylate ...

Osimertinib plus savolitinib demonstrated stronger efficacy than osimertinib alone in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC in the FLOWERS study.

Information for the public Osimertinib (Tagrisso) is available on the NHS as a possible adjuvant treatment option for stage 1b to 3a non-small-cell lung cancer after the tumour has been completely ...

Osimertinib with Chemotherapy in EGFR -Mutated NSCLC November 22, 2023 DOI: 10.1056/NEJMdo007286 ...